Dr. Shevrin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2650 Ridge Ave
Div. Of Hematology/Oncology
Evanston, IL 60201Phone+1 847-570-2515Fax+1 847-570-2336- Is this information wrong?
Education & Training
- University of Illinois College of Medicine at Chicago/Michael Reese HospitalFellowship, Hematology and Medical Oncology, 1981 - 1984
- University of Illinois College of Medicine at ChicagoResidency, Internal Medicine, 1979 - 1984
- University of Kansas School of MedicineClass of 1977
Certifications & Licensure
- IL State Medical License 1979 - 2026
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
- Super Doctor SuperDoctors.com
Clinical Trials
- Study of Erlotinib in Patients With Non-Metastatic Prostate Cancer With a Rising Prostate Specific Antigen (PSA) on Hormone Therapy Start of enrollment: 2005 Aug 01
- Effect of Dutasteride on Androgen-Response Gene Expression in Patients With Advanced Prostate Cancer Start of enrollment: 2007 Mar 01
- Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer Start of enrollment: 2012 Mar 30
- Join now to see all
Publications & Presentations
PubMed
- 1813 citationsChemohormonal Therapy in Metastatic Hormone-Sensitive Prostate CancerChristopher Sweeney, Yu-Hui Chen, Michael A. Carducci, Glenn Liu, David F. Jarrard
The New England Journal of Medicine. 2015-08-19 - 602 citationsChemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED TrialChristos Kyriakopoulos, Yu-Hui Chen, Michael A. Carducci, Glenn Liu, David F. Jarrard
Journal of Clinical Oncology. 2018-01-31 - 74 citationsSeven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel.Lauren C. Harshman, Yu-Hui Chen, Glenn Liu, Michael A. Carducci, David F. Jarrard
Journal of Clinical Oncology. 2017-12-20
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: